Zoledronic acid protects against local and systemic bone loss in tumor necrosis factor–mediated arthritis
Open Access
- 6 July 2004
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 50 (7) , 2327-2337
- https://doi.org/10.1002/art.20384
Abstract
Objective Increased osteoclast activity is a key factor in bone loss in rheumatoid arthritis (RA). This suggests that osteoclast‐targeted therapies could effectively prevent skeletal damage in patients with RA. Zoledronic acid (ZA) is one of the most potent agents for blocking osteoclast function. We therefore investigated whether ZA can inhibit the bone loss associated with chronic inflammatory conditions. Methods Human tumor necrosis factor (TNF)–transgenic (hTNFtg) mice, which develop severe destructive arthritis as well as osteoporosis, were treated with phosphate buffered saline, single or repeated doses of ZA, calcitonin, or anti‐TNF, at the onset of arthritis. Results Synovial inflammation was not affected by ZA. In contrast, bone erosion was retarded by a single dose of ZA (−60%) and was almost completely blocked by repeated administration of ZA (−95%). Cartilage damage was partly inhibited, and synovial osteoclast counts were significantly reduced with ZA treatment. Systemic bone mass dramatically increased in hTNFtg mice after administration of ZA, which was attributable to an increase in trabecular number and connectivity. In addition, bone resorption parameters were significantly lowered after administration of ZA. Calcitonin had no effect on synovial inflammation, bone erosion, cartilage damage, or systemic bone mass. Anti‐TNF entirely blocked synovial inflammation, bone erosion, synovial osteoclast formation, and cartilage damage but had only minor effects on systemic bone mass. Conclusion ZA appears to be an effective tool for protecting bone from arthritic damage. In addition to their role in antiinflammatory drug therapy, modern bisphosphonates are promising candidates for maintaining joint integrity and reversing systemic bone loss in patients with arthritis.Keywords
Funding Information
- Center of Molecular Medicine of the Austrian Federal Ministry for Education, Science and Culture
- City of Vienna
- Austrian National Bank (8715)
- Austrian Ministry of Sciences
This publication has 31 references indexed in Scilit:
- Tumor necrosis factor α‐mediated joint destruction is inhibited by targeting osteoclasts with osteoprotegerinArthritis & Rheumatism, 2002
- Intravenous Zoledronic Acid in Postmenopausal Women with Low Bone Mineral DensityNew England Journal of Medicine, 2002
- Preclinical studies with zoledronic acid and other bisphosphonates: Impact on the bone microenvironmentSeminars in Oncology, 2001
- TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligandJournal of Clinical Investigation, 2000
- IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosionJournal of Clinical Investigation, 2000
- A comparison of the skeletal effects of intermittent and continuous administration of calcitonin in ovariectomized ratsBone, 1996
- ROLE OF CYTOKINES IN RHEUMATOID ARTHRITISAnnual Review of Immunology, 1996
- CONSTITUTIVE mRNA AND PROTEIN PRODUCTION OF MACROPHAGE COLONY-STIMULATING FACTOR BUT NOT OF OTHER CYTOKINES BY SYNOVIAL FIBROBLASTS FROM RHEUMATOID ARTHRITIS AND OSTEOARTHRITIS PATIENTSRheumatology, 1994
- Bone histomorphometry: Standardization of nomenclature, symbols, and units: Report of the asbmr histomorphometry nomenclature committeeJournal of Bone and Mineral Research, 1987
- Chondroclasts and osteoclasts at subchondral sites of erosion in the rheumatoid jointArthritis & Rheumatism, 1984